Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.
Actively Recruiting
Healthy Volunteer
Obesity greatly increases the risk of heart failure, and current treatments like caloric restriction, exercise, medications, or surgery may not be suitable for obese patients with heart failure. This research aims to study whether a combined approach using a diet management app and an intelligent weight scale can help obese patients with heart failure and reduced ejection fraction lose weight and improve their heart condition. The trial compares the effectiveness of a fully functional app and scale versus a limited-function version to assess their impact on heart failure outcomes and overall quality of life. Participants are randomly assigned to two groups one using a fully featured diet management app and intelligent weight scale with various monitoring tools and health metrics, and the other using a limited version of both. The full app tracks food intake, exercise, weight, and provides dietary analysis and recommendations, while the full scale measures body composition and vital signs. The limited versions offer fewer features. Participants use the app at every meal and weigh themselves daily for 12 months. During the study, participants will visit the clinic at 12 months for checkups. Researchers will evaluate outcomes such as a composite of death and heart failure hospitalizations over one year, changes in quality of life related to heart failure, and weight change. The trial includes monitoring of heart failure frailty and quality of life assessments at baseline, 3 months, and 1 year, with ongoing safety and condition tracking throughout the study period.
Actively Recruiting
Researchers are evaluating a treatment for people with spontaneous supratentorial intracerebral hemorrhage ICH, a serious type of stroke caused by bleeding in the brain. The study is a phase III randomized controlled trial that will involve 768 participants to compare a new minimally invasive surgery combined with a clot-dissolving drug against standard medical care. This trial aims to assess the safety and effectiveness of using tenecteplase to liquefy and drain brain hematomas, potentially improving recovery outcomes. Participants will be randomly assigned to one of two groups. One group will receive minimally invasive stereotactic catheter placement followed by the local injection of tenecteplase to liquefy and drain the hematoma, with doses of 0.5 mg given up to four times over several days. The other group will receive standard medical treatment in line with current guidelines. The surgery uses imaging to target the hematoma, and after catheter placement, tenecteplase is carefully administered through the catheter with close monitoring. Throughout the study, participants will undergo regular assessments including neurological exams, brain imaging, and functional outcome evaluations up to 180 days after treatment. The main measurement is the modified Rankin Score assessing disability and recovery. Other outcomes include neurological improvement, hematoma size, mortality, and quality of life. Follow-up visits may be conducted face-to-face or remotely, and researchers will carefully monitor safety and treatment effects during this period.